# US 2013/0259887 A1 · Reovirus vaccines and methods of use therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0259887 A1
- Document ID: US20130259887A1
- Status: Published application
- Kind: A1
- Application number: 13/639,564
- Filed: 2011-04-04
- Published: 2013-10-03
- Earliest claimed: 2010-04-07
- Assignees: Vanderbilt University
- Inventors: Terence S. Dermody; Karl W. Boehme; Mine Ikizler; Gregory J. Wilson; James D. Chappell
- Web page: https://patentgrep.com/patent/US20130259887A1

## CPC

- C07K 14/14: Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
- A61K 39/12: Viral antigens
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- C07K 14/005: from viruses
- A61K 2039/5256: {expressing foreign proteins}
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C12N 2720/12222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2720/12243: viral genome or elements thereof as genetic vector
- C12N 2740/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides for modified reoviruses that carry α-helical epitopes from a variety of pathogens, as well as methods of using such modified reoviruses to generate immune responses against those epitopes in hosts.

## Claims

### Claim 1

A modified reovirus σ1 protein comprising a first antigenic epitope from a non-reovirus antigen located in α-helical region of said protein.

### Claim 2 (depends on 1)

The modified reovirus σ1 protein of claim 1, wherein said first epitope is inserted into said α-helical region of said protein.

### Claim 3 (depends on 1)

The modified reovirus σ1 protein of claim 1, wherein said first epitope replaces one or more heptad repeats in said α-helical region of said protein.

### Claim 4 (depends on 1)

The modified reovirus σ1 protein of claim 1, wherein said first epitope is a viral epitope.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The modified reovirus σ1 protein of claim 1, wherein said first epitope is a bacterial epitope.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The modified reovirus σ1 protein of claim 1, wherein said first epitope is a fungal epitope or a parasite epitope.

### Claim at position 9

9-40. (canceled)

### Claim 41

A reovirus vector encoding a reovirus σ1 protein comprising a first antigenic epitope from a non-reovirus antigen located in α-helical region of said protein.

### Claim at position 11

42-50. (canceled)

### Claim 51

A reovirus particle comprising a vector encoding a reovirus σ1 protein comprising a first antigenic epitope from a non-reovirus antigen located in α-helical region of said protein.

### Claim 52 (depends on 51)

The reovirus particle of claim 51, wherein said first epitope is inserted into said α-helical region of said protein.

### Claim 53 (depends on 51)

The reovirus particle of claim 51, wherein said first epitope replaces one or more heptad repeats in said α-helical region of said protein.

### Claim 54 (depends on 51)

The reovirus particle of claim 51, wherein said first epitope is a viral epitope, a bacterial epitope, or a fungal epitope.

### Claim 55 (depends on 51)

The reovirus particle of claim 51, further comprising a second copy of said first epitope in said α-helical region.

### Claim 56 (depends on 56)

The reovirus particle of claim 56, wherein said second copy is inserted into said α-helical region of said protein.

### Claim 57 (depends on 56)

The reovirus particle of claim 56, wherein said second copy replaces one or more heptad repeats in said α-helical region of said protein.

### Claim at position 19

58-60. (canceled)

### Claim 61

A method of inducing an immune response in a subject comprising providing to said subject a modified reovirus σ1 protein comprising a first antigenic epitope from a non-reovirus antigen located in α-helical region of said protein.

### Claim 62 (depends on 61)

The method of claim 61, wherein said first epitope is inserted into said a-helical region of said protein.

### Claim 63 (depends on 61)

The method of claim 61, wherein said first epitope replaces one or more heptad repeats in said α-helical region of said protein.

### Claim 64 (depends on 61)

The method of claim 61, wherein said first epitope is a viral epitope.

### Claim 65

(canceled)

### Claim 66 (depends on 61)

The method of claim 61, wherein said first epitope is a bacterial epitope.

### Claim 67

(canceled)

### Claim 68 (depends on 61)

The method of claim 61, wherein said first epitope is a fungal epitope or a parasite epitope.

### Claim at position 28

69-79. (canceled)

### Claim 80 (depends on 72)

The method of claim 72, wherein said second epitope replaces one or more heptad repeats in said α-helical region of said protein.

### Claim 81 (depends on 61)

The method of claim 61, wherein providing comprises administering said modified reovirus σ1 protein.

### Claim 82

(canceled)

### Claim 83 (depends on 61)

The method of claim 61, wherein providing comprises administering a vector encoding said modified reovirus σ1 protein.

### Claim 84

(canceled)

### Claim 85 (depends on 61)

The method of claim 61, wherein providing comprises administering a viral particle comprising a vector encoding said modified reovirus σ1 protein.

### Claim at position 35

86-100. (canceled)

### Claim 101

A method of expressing an epitope in a subject comprising providing to said subject a modified reovirus σ1 protein comprising a first antigenic epitope from an antigen located in α-helical region of said protein.

### Claim at position 37

102-108. (canceled)
